Thu, August 27, 2020
Wed, August 26, 2020
Tue, August 25, 2020
Mon, August 24, 2020

Danielle Brill Initiated (SRPT) at Buy and Held Target at $200 on, Aug 25th, 2020

Danielle Brill of Raymond James, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $200 on, Aug 25th, 2020.

Danielle has made no other calls on SRPT in the last 4 months.



There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 1 agrees with Danielle's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Martin Auster of "Credit Suisse" Downgraded from Buy to Hold and Decreased Target to $167 on, Thursday, August 20th, 2020


These are the ratings of the 2 analyists that currently disagree with Danielle


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $182 on, Monday, August 10th, 2020
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $180 on, Wednesday, June 10th, 2020